Asset profile
Eltanexor
Unknown / undisclosed
Evidence outlook · lead readout
NCT02649790 · Relapsed/Refractory Multiple Myeloma (RRMM), Metastatic Colorectal Cancer (mCRC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Higher-Risk Myelodysplastic Syndrome (HR-MDS), Acute Myeloid Leukemia (AML), Newly Diagnosed Intermediate/High-Risk MDS
The reported results come from study designs that frequently fail to replicate under controlled conditions — see the rationale below.
NCT02649790: The study was nonrandomized, open-label, sequential, and had no comparator arm; its estimated enrollment was 277 participants across multiple cancer indications. Although it included clinical endpoints such as response, progression-free survival, and overall survival, no primary endpoint results are posted.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.